| Literature DB >> 17443037 |
Hiroki Tahara1, Akira Kojima, Tomoyuki Hirokawa, Tatsuya Oyama, Atsushi Naganuma, Sakae Maruta, Katsuyuki Okada, Satoshi Ban, Katsue Yoshida, Hitoshi Takagi, Masatomo Mori.
Abstract
A 66-year-old woman developed systemic sclerosis (SSc) after receiving interferon alphacon-1 (IFNalphacon-1; consensus interferon) therapy for chronic hepatitis C. She suffered from Raynauds phenomenon about 1 year after a course of IFNalphacon-1 therapy. The combination of proximal scleroderma, Raynauds phenomenon, and ANA positivity led to a diagnosis of systemic sclerosis (SSc). IFN has multiple effects on the immune system and is known to trigger the development of autoantibodies, as well as the onset or exacerbation of autoimmune disease. We suspect that the immunomodulatory effects of IFNalphacon-1 triggered the clinical manifestations of SSc in this patient. To our knowledge this is only the third case of SSc after IFNalpha therapy, and it is the first case associated with IFNalphacon-1 therapy.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17443037 DOI： 10.2169/internalmedicine.46.6328
Source DB: PubMed Journal: Intern Med ISSN： 0918-2918 Impact factor: 1.271